glp-1 patch clinical trial transdermal semaglutide patch Single-Administration Self-Boosting Microneedle for The Treatment of Obesity Single-Administration Self-Boosting Microneedle Patch for
Description
On GLP-1s
About 1 in 8 Americans have used GLP-1 drugs
Patients lose avg 9.6 lbs in 30 days
In Metabolic Dysfunction-Associated Steatotic Liver Disease, GLP-1 RAs and GIP/GLP-1 RAs demonstrate marked histological improvements
New Study Highlights Hair Regrowth in a Male with Balding Using Terzepatide
